Hematopoietic stem cell transplantation and protection from disability progression in multiple sclerosis

  • Autologous hematopoietic stem cell transplantation (AHSCT) resulted in significantly longer time to first incidence of confirmed disability progression compared to other anti-inflammatory disease modifying therapies (DMT; P=0.005).
  • AHSCT-treated individuals also reported lower Expanded Disability Status Scale scores over a 10-year period and were more likely experience sustained disability improvement (P<0.001) than those treated with anti-inflammatory DMT (P<0.001).
  • The authors concluded that AHSCT has the potential to slow and potentially reverse disability progression for individuals with active secondary progressive multiple sclerosis.